Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial

被引：0
|
作者：
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Toronto, Toronto, ON, Canada
[5] McGill Univ, Montreal, PQ, Canada
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [41] Daclizumab phase I/II trial in relapsing-remitting multiple sclerosis: MRI and clinical results
    Rose, J.
    Burns, J.
    Bjorklund, J.
    Klein, J.
    Watt, H.
    Carlson, N.
    [J]. MULTIPLE SCLEROSIS, 2006, 12 : S105 - S105
  • [42] Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
    Gold, Ralf
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Montalban, Xavier
    Radue, Ernst-Wilhelm
    Stefoski, Dusan
    Robinson, Randy
    Riester, Katherine
    Rana, Jitesh
    Elkins, Jacob
    O'Neill, Gilmore
    [J]. LANCET, 2013, 381 (9884): : 2167 - 2175
  • [43] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    [J]. NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [44] Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Hamlett, Anthony
    Scaramozza, Matthew
    Lachenal, Nathalie
    [J]. NEUROLOGY, 2013, 80
  • [45] Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial
    Fleming, John
    Hernandez, Gianna
    Hartman, Leslie
    Maksimovic, Jane
    Nace, Sara
    Lawler, Benjamin
    Risa, Todd
    Cook, Thomas
    Agni, Rashmi
    Reichelderfer, Mark
    Luzzio, Christopher
    Rolak, Loren
    Field, Aaron
    Fabry, Zsuzsanna
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (01) : 81 - 91
  • [46] Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
    Sorensen, Per Soelberg
    Lycke, Jan
    Eralinna, Juha-Pekka
    Edland, Astrid
    Wu, Xingchen
    Frederiksen, Jette Lautrup
    Oturai, Annette
    Malmestrom, Clas
    Stenager, Egon
    Sellebjerg, Finn
    Sondergaard, Helle Bach
    [J]. LANCET NEUROLOGY, 2011, 10 (08): : 691 - 701
  • [47] Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One) a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
    Brown, J. William L.
    Cunniffe, Nick G.
    Prados, Ferran
    Kanber, Baris
    Jones, Joanne L.
    Needham, Edward
    Georgieva, Zoya
    Rog, David
    Pearson, Owen R.
    Overell, James
    MacManus, David
    Samson, Rebecca S.
    Stutters, Jonathan
    Ffrench-Constant, Charles
    Wheeler-Kingshott, Claudia A. M. Gandini
    Moran, Carla
    Flynn, Paul D.
    Michell, Andrew W.
    Franklin, Robin J. M.
    Chandran, Siddharthan
    Altmann, Daniel R.
    Chard, Declan T.
    Connick, Peter
    Coles, Alasdair J.
    [J]. LANCET NEUROLOGY, 2021, 20 (09): : 709 - 720
  • [48] A randomised, double-blind, placebo-controlled, multi-centre trial to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis optica: the PREVENT study
    Wingerchuk, D. M.
    Palace, J.
    Cavus, I.
    O'Brien, F.
    Pittock, S. J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 759 - 759
  • [49] The efficacy of cladribine in relapsing-remitting multiple sclerosis: Magnetic resonance imaging data from a randomized, double blind, placebo-controlled, 18-month, phase II trial
    Sipe, Jack C.
    Gardner, Jason
    Beutler, Ernest
    [J]. NEUROLOGY, 2008, 70 (11) : A105 - A105
  • [50] Targeted therapy of relapsing-remitting multiple sclerosis with interferon β-1b: results of a Polish multi-centre survey
    Wygladalska-Jernas, H.
    Tokarz-Kupczyk, E.
    Kozubski, W.
    Gryz-Kurek, E.
    Rog, T.
    Nocon, D.
    Hozejowski, R.
    Kozlowska-Boszko, B.
    [J]. JOURNAL OF NEUROLOGY, 2009, 256 : S239 - S239
12345